Akebia TherapeuticsSTU:AX9 +8.59%51 PB Ratio is 11.12 as of Jun. 29, 2026, which is 214% above its 10-year median of 3.54. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.12 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Akebia Therapeutics ranks worse than 92.95% on this metric.
The historical rank and industry rank for Akebia Therapeutics's PB Ratio or its related term are showing as below:
STU:AX9'
s PB Ratio Range Over the Past 10 Years
Min: 0.85 Med: 3.54 Max: 42.23
Current: 11.18
During the past 13 years, Akebia Therapeutics's highest PB Ratio was 42.23. The lowest was 0.85. And the median was 3.54.
STU:AX9's PB Ratio is ranked worse than 92.95% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.845
vs STU:AX9: 11.18
During the past 12 months, Akebia Therapeutics's average Book Value Per Share Growth Rate was 8.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 63.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Akebia Therapeutics was 63.80% per year. The lowest was -79.50% per year. And the median was -13.40% per year.
Back to Basics: PB Ratio
Akebia Therapeutics (STU:AX9) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Akebia Therapeutics PB Ratio Related Terms
Akebia Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Akebia Therapeutics (STU:AX9) has a PB Ratio of 11.12 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Akebia Therapeutics and its competitors. This is 214% above median its historical median of 3.54. Over the past decade, Akebia Therapeutics' PB Ratio has ranged from 0.85 to 42.23. According to the industry distribution chart, Akebia Therapeutics ranks #857 out of 922 companies in the Drug Manufacturers industry, placing it in the top 93%.
Is Akebia Therapeutics' PB Ratio too high?
Akebia Therapeutics' current PB Ratio of 11.12 is 214% above median its 10-year median of 3.54. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 42.23. The Drug Manufacturers industry median PB Ratio is 1.85. Akebia Therapeutics' value of 11.12 is 502.7% above this industry median. Based on the distribution chart, Akebia Therapeutics ranks #857 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' PB Ratio compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #857 out of 922 companies for PB Ratio. This places Akebia Therapeutics in the lower half of its industry. The industry median PB Ratio is 1.85. Akebia Therapeutics' value of 11.12 is 502.7% above this benchmark. Historically, Akebia Therapeutics' own PB Ratio has ranged from 0.85 to 42.23 over the past decade. While the company's 10-year median is 3.54 vs. the industry median of 1.85, Akebia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.85, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current PB Ratio of 11.12 is 502.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current PB Ratio is 11.12, which is 214% above median its own 10-year median of 3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.12, compared to a current price of €0.98 — trading 12.6% below its estimated fair value. The current PB Ratio is 11.12, which is 214% above median its 10-year median of 3.54 and 502.7% above the Drug Manufacturers industry median of 1.85. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current PB Ratio is 11.12 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.98 is trading 12.6% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AX9:
PB Ratio: 11.12 (214% above median its 10-year median of 3.54)
GF Value™: €1.12 vs. price of €0.98 (12.6% below fair value)
Industry Position: 502.7% above the Drug Manufacturers median (#857 of 922)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score
Get the complete analysis for STU:AX9
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
